The American Journal of Managed Care12 小时
Phase 3 Data Support Nipocalimab for Myasthenia Gravis
The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...
来自MSN1 天
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast Cancer
For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 ...
verywellhealth1 天
A New 'Missile' Drug Is Approved To Treat the Most Common Breast Cancer Type
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
oncnursingnews2 天
T-DXd Companion Diagnostic in HER2-Ultralow Metastatic Breast Cancer Gains FDA Approval
The FDA has approved a companion diagnostic to determine if patients with HR-positive, HER2-ultralow metastatic breast cancer are eligible for T-DXd treatment.
MedPage Today4 天
Heart Protection With SGLT2, GLP-1 Drugs for Diabetes Mediated by Age
GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...
Medigene AG announces closing of its first SEPA tranche
The gross proceeds of approximately EUR 0.25 million will be used to fund business operations.
interaksyon.philstar5 天
No, we’re not ‘one mutation away’ from an H5N1 bird flu pandemic – here are the facts
In early December 2024, a group of researchers published an article in the journal Science, entitled “A single mutation in ...
oncnursingnews11 天
FDA Approves T-DXd for Previously Treated HER2-Low and -Ultralow Metastatic Breast Cancer
T-DXd has received FDA approval for the treatment of unresectable or metastatic HR+, HER2-low/-ultralow breast cancer in ...
Targeted Oncology11 天
FDA Approves T-DXd in HR+, HER2-Low/Ultralow Breast Cancer
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...